Loading
companiesCompany
Ariceum Therapeutics
Ariceum Therapeutics is a Berlin company developing a treatment that carries the alpha-emitting isotope actinium-225 to small cell lung cancer and Merkel cell skin cancer. Its first human trial began in late 2025.
Overview
Ariceum Therapeutics is a Berlin-based targeted radiotherapeutics company. Its lead candidate 225Ac-SSO110 is an actinium-225 labelled radioligand for extensive-stage small cell lung cancer (ES-SCLC) and Merkel cell carcinoma (MCC); the phase 1/2 SANTANA-225 study was planned to start in the second half of 2025, with initial safety data expected in early 2026 and preliminary efficacy findings in 2027. In August 2025 David Schilansky, previously CFO, succeeded co-founder Manfred Rüdiger as CEO alongside a new executive team.
Notes
top- Company website ariceum-therapeutics.com returned a certificate error and then an HTTP 500 'Database Error' on every attempt, so the website field points to the fetched release copy. Series A (reported elsewhere as EUR 25 million in 2022) and the Theragnostics acquisition are unsourced and omitted. SSO110 target (SSTR2 antagonist per other reports) not stated in the fetched text.
Similar pages
- CompanyRatio Therapeutics
Shares Targeted alpha therapy, Radioligand therapy (beta emitters).
- IdeaA global medical isotope supply observatory with forecasts and shortage alerts
Shares Targeted alpha therapy, Radioligand therapy (beta emitters).
- CompanyARTBIO
Shares Targeted alpha therapy, Radioligand therapy (beta emitters).
- CompanyAbdera Therapeutics
Shares Targeted alpha therapy, Radioligand therapy (beta emitters), Small-cell lung cancer.
- CompanyEvergreen Theragnostics
Shares Radioligand therapy (beta emitters), Small-cell lung cancer.
- TechnologyAstatine-211 alpha therapy
Shares Targeted alpha therapy, Radioligand therapy (beta emitters).
- TechnologyRadioligand dosimetry
Shares Targeted alpha therapy, Radioligand therapy (beta emitters).
- IdeaRecover legacy radium-226 sources worldwide as the feedstock for actinium-225
Shares Targeted alpha therapy, Radioligand therapy (beta emitters).